AZA1 Rac1/Cdc42-IN-1|cas:1071098-42-4|西域试剂

AZA1 Rac1/Cdc42-IN-1,98.07%

产品编号：Bellancom-136383| CAS NO：1071098-42-4| 分子式：C₂₂H₂₀N₆| 分子量：368.43

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136383	￥3000.00	杭州北京（现货）
Bellancom-136383	￥4800.00	杭州北京（现货）
Bellancom-136383	￥13500.00	杭州北京（现货）
Bellancom-136383	￥19500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AZA1 Rac1/Cdc42-IN-1

产品介绍

AZA1 是 Rac1 和 Cdc42 的有效抑制剂。AZA1 诱导前列腺癌细胞凋亡并抑制增殖，迁移和侵袭。

生物活性

AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion.

体外研究

AZA1 (Rac1/Cdc42-IN-1) (2-10 μM; 72 hours) blocks the proliferation of human prostate cancer cells 22Rv1 prostate cancer cells.
AZA1 (2-10 μM; 24 hours) reduces phosphorylation of PAK1, AKT and BAD in EGF-stimulated 22Rv1 prostate cancer cells.
AZA1 (10 μM; 24 hours) blocks Rac1 and Cdc42-dependent cell cycle events in 22Rv1 prostate cancer cells.
AZA1 blocks Rac1 and Cdc42-dependent migration of 22Rv1, DU 145 and PC-3 prostate cancer cells.
AZA1 affects cell motility and actin rearrangement in prostate cancer cells by suppressing Rac1 and Cdc42 activity via PAK1/2 phosphorylation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	22Rv1 prostate cancer cells
Concentration:	2, 5, 10 μM
Incubation Time:	72 hours
Result:	Suppressed 22Rv1 prostate cancer cell proliferation in both unstimulated and EGF-stimulated cancer cells in a dose-dependent manner.

Western Blot Analysis

Cell Line:	22Rv1 prostate cancer cells (EGF-stimulated)
Concentration:	2, 5, 10 μM
Incubation Time:	24 hours
Result:	Reduced phosphorylation of PAK1, AKT and BAD in EGF-stimulated 22Rv1 prostate cancer cells.

体内研究
(In Vivo)

AZA1 (Rac1/Cdc42-IN-1) (100 μg; i.p.; daily for 2 weeks) is potent in suppressing human 22Rv1 xenograft growth in mice and improving survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week-old athymic nu/nu (nude) mice (bearing 22Rv1 prostate cancer cell xenografts)
Dosage:	100 μg in 100 µl 30% DMSO
Administration:	I.p.; daily for 2 weeks
Result:	The suppressive effect of AZA1 on tumor growth was significant.

体内研究

AZA1 (Rac1/Cdc42-IN-1) (100 μg; i.p.; daily for 2 weeks) is potent in suppressing human 22Rv1 xenograft growth in mice and improving survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week-old athymic nu/nu (nude) mice (bearing 22Rv1 prostate cancer cell xenografts)
Dosage:	100 μg in 100 µl 30% DMSO
Administration:	I.p.; daily for 2 weeks
Result:	The suppressive effect of AZA1 on tumor growth was significant.

体内研究

AZA1 (Rac1/Cdc42-IN-1) (100 μg; i.p.; daily for 2 weeks) is potent in suppressing human 22Rv1 xenograft growth in mice and improving survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5 week-old athymic nu/nu (nude) mice (bearing 22Rv1 prostate cancer cell xenografts)
Dosage:	100 μg in 100 µl 30% DMSO
Administration:	I.p.; daily for 2 weeks
Result:	The suppressive effect of AZA1 on tumor growth was significant.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (135.71 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7142 mL	13.5711 mL	27.1422 mL
5 mM	0.5428 mL	2.7142 mL	5.4284 mL
10 mM	0.2714 mL	1.3571 mL	2.7142 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.79 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.79 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明